Special lssues

Technology system of fecal microbiota transplantation

  • ZHANG Faming
  • Key Lab of Holistic Integrative Enterology, Nanjing Medical University;Center for Intestinal Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China

Received date: 2016-09-29

  Revised date: 2016-10-12

  Online published: 2016-11-05


The fecal microbiota transplantation (FMT), as the core therapy strategy for remodeling the gut microbiota adopted generally for a long medical history, has gained a great attention in the world. Though it has been used as a guideline-approved treatment for the recurrent Clostridium difficile infection and a potential option for microbiota-related diseases, the FMT has not been used very well world widely mainly due to the methodology limitation. The fmtBank is a non-profit institute in China, with its core based on the technology system of the FMT. This paper mainly focuses on the medical history, the methodology system of the non-profit fmtBank, and the safety, the ethical problem, the policy and the future direction of the FMT.

Cite this article

ZHANG Faming . Technology system of fecal microbiota transplantation[J]. Science & Technology Review, 2016 , 34(20) : 86 -92 . DOI: 10.3981/j.issn.1000-7857.2016.20.014


[1] Borody T J, Khoruts A. Fecal microbiota transplantation and emerging applications[J]. Nature Reviews Gastroenterology & Hepatology, 2012, 9(2):88-96.
[2] Zhang F, Luo W, Shi Y, et al. Should we standardize the 1700-year-old fecal microbiota transplantation?[J]. American Journal of Gastroenterology, 2012, 107(11):1755.
[3] Eiseman B, Silen W, Bascom G S, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis[J]. Surgery, 1958, 44(5):854-859.
[4] 崔伯塔, 李潘, 彭炤源, 等. 粪菌移植:2014年进展[J]. 中华消化内镜杂志, 2015, 32(9):643-646.
[5] Freeman J, Bauer M P, Baines S D, et al. The changing epidemiology of Clostridium difficile infections[J]. Clinical Microbiology Reviews, 2010, 23(3):529-549.
[6] Kelly C P, LaMont J T. Clostridium difficile:More difficult than ever[J]. New England Journal of Medicine, 2008, 359(18):1932-1940.
[7] Surawicz C M, Brandt L J, Binion D G, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections[J]. American Journal of Gastroenterology, 2013, 108(4):478-498.
[8] Zhang F M, Wang H G, Wang M, et al. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease[J]. World Journal of Gastroenterology, 2013, 19(41):7213-7216.
[9] Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation strategy:A pilot study for steroid-dependent ulcerative colitis[J]. Journal of Translational Medicine, 2015, 13:298.
[10] Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation (FMT) strategy[J]. Gut Microbes, 2016. doi:10.1080/19490976.2016.1151608.
[11] Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant/dependent acute graft-versus-host disease of the gut[J]. Blood, 2016. pii:blood-2016-05-717652.
[12] Rossen N G, Fuentes S, van der Spek M J, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis[J]. Gastroenterology, 2015, 149(1):110-118.
[13] Kelly C R, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection:A randomized trial[J]. Annals of Internal Medicine, 2016. doi:10.7326/M16-0271.
[14] Brandt L J, Aroniadis O C. An overview of fecal microbiota transplantation:Techniques, indications, and outcomes[J]. Gastrointestinal Endoscopy, 2013, 78(2):240-249.
[15] Seekatz A M, Aas J, Gessert C E, et al. Recovery of the gut microbiome following fecal microbiota transplantation[J]. mBio, 2014, 5(3):e00893-e00914.
[16] Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation[J]. American Journal of Gastroenterology, 2013, 108(10):1620-1630.
[17] Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease:Safety, feasibility, and efficacy trial results[J]. Journal of Gastroenterology and Hepatology, 2015, 30(1):51-58.
[18] Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives[J]. Gut, 2011, 60(5):631-637.
[19] 李时珍(明). 本草纲目[M]. 北京:华夏出版社, 2011.
[20] Petrof E O, Gloor G B, Vanner S J, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection:'RePOOPulating' the gut[J]. Microbiome, 2013, 1(1):3.
[21] Zhang F. Is fecal microbiota transplantation trough the mid-gut a rescue terapy for refractory IBD[J]. World Gastroenterology News, 2014, 19(2):4-5.
[22] Moayyedi P, Surette M G, Kim P T, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J]. Gastroenterology, 2015, 149(1):102-109.
[23] Cui B, Xu F, Zhang F. Methodology, not concept of fecal microbiota transplantation, affects clinical findings[J]. Gastroenterology, 2016, 150(1):285-286.
[24] Ulluwishewa D, Anderson R C, Young W, et al. Live Faecalibacterium prausnitzii in an apical anaerobic model of the intestinal epithelial barrier[J]. Cell Microbiology, 2015, 17(2):226-240.
[25] Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing:A novel way of transplanting fecal microbiota[J]. Endoscopy International Open, 2016, 4(6):E610-E613.
[26] Colman R J, Rubin D T. Fecal microbiota transplantation as therapy for inflammatory bowel disease:A systematic review and meta-analysis[J]. Journal of Crohns & Colitis, 2014, 8(12):1569-1581.
[27] Sha S, Liang J, Chen M, et al. Systematic review:Faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children[J]. Alimentary Pharmacology & Therapeutics, 2014, 39(10):1003-1032.
[28] Anderson J L, Edney R J, Whelan K. Systematic review:Faecal microbiota transplantation in the management of inflammatory bowel disease[J]. Alimentary Pharmacology & Therapeutics, 2012, 36(6):503-516.
[29] van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile[J]. New England Journal of Medicine, 2013, 368(5):407-415.
[30] Fischer M, Kao D, Mehta S R, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection:A multicenter study[J]. American Journal of Gastroenterology, 2016, 111(7):1024-1031.
[31] Suskind D L, Brittnacher M J, Wahbeh G, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease[J]. InflammatoryBowel Diseases, 2015, 21(3):556-563.
[32] Fan D. Holistic integrative medicine[J]. American Journal of Digestive Disease, 2014, 1(1):22-36.
[33] Shimizu H, Arai K, Abe J, et al. Repeated fecal microbiota transplantation in a child with ulcerative colitis[J]. Pediatrics International, 2016, 58(8):781-785.
[34] Xu L, Zhang T, Cui B, et al. Clinical efficacy maintains patients' positive attitudes toward fecal microbiota transplantation[J]. Medicine, 2016, 95(30):e4055.
[35] Zhang T, Cui B, Li P, et al. Short-term surveillance of cytokines and C-reactive protein cannot predict efficacy of fecal microbiota transplantation for ulcerative colitis[J]. PLoS One, 2016, 11(6):e0158227.
[36] Kelly C R, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients[J]. American Journal of Gastroenterology, 2014, 109(7):1065-1071.
[37] Hohmann E L, Ananthakrishnan A N, Deshpande V. Case records of the massachusetts general hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea[J]. New England Journal of Medicine, 2014, 371(7):668-675.
[38] 张发明, 范志宁, 季国忠. 粪菌移植的概念、历史、现状和未来[J]. 中国内镜杂志, 2012(9):930-934.
[39] Kellermayer R. Prospects and challenges for intestinal microbiome therapy in pediatric gastrointestinal disorders[J]. World Journal of Gastrointestinal Pathophysiology, 2013, 4(4):91-93.